Trial Profile
The Compatibility of Nivestim Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Filgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia; Neutropenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms VENICE
- Sponsors Hospira
- 14 Oct 2016 Results published in the Advances in Therapy
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 14 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.